HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
To evaluate the safety and efficacy of HRS-4642 in combination with gemcitabine and albumin-bound paclitaxel for the neoadjuvant and adjuvant treatment of pancreatic ductal adenocarcinoma.
Pancreatic Cancer
DRUG: HRS-4642
Adverse events (AEs), AEs are assessed by NCI-CTCAE v5.0, From the first drug administration to within 30 days for the last dose|R0 resection rate, Number of Subjects Achieving R0 Removal as a Percentage of Subjects, At the time of surgery
Total resection rate, Percentage of subjects who received surgical treatment as a proportion of all subjects, At the time of surgery|pathologic complete response (pCR), Number of subjects achieving pCR as a percentage of subjects, At the time of surgery|major pathologic response (MPR), Number of Subjects Achieving MPR as a Percentage of Subjects, At the time of surgery|Objective Response Rate (ORR), Evaluated by RECIST v1.1, Up to approximately 6 months|Disease-free survival (DFS), The time from adjuvant therapy to the occurrence of disease recurrence (local recurrence or distant recurrence) or death from any cause in subjects achieving R0/R1 resection is counted as occurring first, Up to approximately 6 months|Event-free survival (EFS), The time from the first dose of neoadjuvant therapy to the occurrence of any event; events include the occurrence of imaging disease progression (based on the date of the imaging test), the occurrence of disease recurrence (local recurrence or distant recurrence) after surgery, and death from any cause, based on the time of the first occurrence, Up to approximately 6 months|Overall survival (OS), Time from the date of enrollment to data of death from any cause, or date of lost follow-up, whichever comes first, and otherwise censored at time last known alive., Up to approximately 12 months
CA19-9 response rate, Up to approximately 6 months
This study is an open, single center, exploratory clinical trial aimed at evaluating the safety and efficacy of HRS-4642 in combination with gemcitabine and albumin-bound paclitaxel for the neoadjuvant and adjuvant treatment of pancreatic ductal adenocarcinoma.